Cited by 231Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin

Open access

Hsia, Judith, MacFadyen, Jean G., Monyak, John, Ridker, Paul M.·2011·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2010.09.082

Open this paper in CoChat — free account Open PDF

Abstract

Objectives The purpose of this study was to assess the impact on cardiovascular and adverse events of attaining low-density lipoprotein cholesterol (LDL-C) levels <50 mg/dl with rosuvastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial.Background The safety and magnitude of cardiovascular risk reduction conferred by treatment to LDL-C levels below current recommended targets remain uncertain.Methods A cohort of 17,802 apparently healthy men and women with high-sensitivity C-reactive protein ≥2 mg/l and LDL-C <130 mg/dl were randomly allocated to rosuvastatin 20 mg daily or placebo, and followed up for all-cause mortality, major cardiovascular events, and adverse events. In a post-hoc analysis, participants allocated to rosuvastatin were categorized as to whether or not they had a follow-up LDL-C level <50 mg/dl.Results During a median follow-up of 2 years (range up to 5 years), rates of the primary trial endpoint were 1.18, 0.86, and 0.44 per 100 person-years in the placebo group (n = 8,150) and rosuvastatin groups without LDL-C <50 mg/dl (n = 4,000) or with LDL-C <50 mg/dl (n = 4,154), respectively (fully-adjusted hazard ratio: 0.76; 95% confidence interval: 0.57 to 1.00 for subjects with no LDL-C <50 mg/dl vs. placebo and 0.35, 95% confidence interval: 0.25 to 0.49 for subjects attaining LDL-C <50 mg/dl; p for trend <0.0001). For all-cause mortality, corresponding event rates were 0.67, 0.65, and 0.39 (p for trend = 0.004). Rates of myalgia, muscle weakness, neuropsychiatric conditions, cancer, and diabetes mellitus were not significantly different among rosuvastatin-allocated participants with and without LDL-C <50 mg/dl.Conclusions Among adults with LDL-C <130 mg/dl and high-sensitivity C-reactive protein ≥2 mg/l, rosuvastatin-allocated participants attaining LDL-C <50 mg/dl had a lower risk of cardiovascular events without a systematic increase in reported adverse events.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2010.09.082

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453

Show all 41 references

Sorted by citations

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citation
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 790
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Self-citation
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial
Robinson, J. G., Nedergaard, B. S., Rogers, W. J., Fialkow, J., Neutel, J. M., Ramstad, D., Somaratne, R., Legg, J. C., Nelson, P., Scott, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.4030 · Cited by 496
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 507
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Self-citation
Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin
Piya, M. K., McTernan, P. G., & Kumar, S. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0498 · Cited by 266
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
KONES, R. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 266
Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ott, B. R., Daiello, L. A., Dahabreh, I. J., Springate, B. A., Bixby, K., Murali, M., & Trikalinos, T. A. (2015) · Journal of General Internal Medicine · doi:10.1007/s11606-014-3115-3 · Cited by 240
Lipid lowering with PCSK9 inhibitors
Dadu, R. T., & Ballantyne, C. M. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.84 · Cited by 234
Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects
Swiger, K. J., Manalac, R. J., Blumenthal, R. S., Blaha, M. J., & Martin, S. S. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.07.013 · Cited by 233
Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
Koren, M. J., Giugliano, R. P., Raal, F. J., SULLIVAN, D. R., Bolognese, M. A., Langslet, G., Civeira, F., Somaratne, R. M., Nelson, P., Liu, T., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.007012 · Cited by 218
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol
Giugliano, R. P., Wiviott, S. D., Blazing, M. A., Ferrari, G. M. D., Park, J., Murphy, S. A., White, J. A., Tershakovec, A. M., Cannon, C. P., & Braunwald, E. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0083 · Cited by 209
Statins: pros and cons
Pinal‐Fernandez, I., Casal-Domínguez, M., & Mammen, A. L. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.030 · Cited by 192
New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
Sahebkar, A., & Watts, G. F. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6479-4 · Cited by 176
Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
Vinci, P., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Girolamo, F. G. D., & Biolo, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111687 · Cited by 188
Non-cardiovascular effects associated with statins
Desai, C. S., Martin, S. S., & Blumenthal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3743 · Cited by 174
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176
The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway
Catapano, A. L., & Papadopoulos, N. J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.044 · Cited by 158
Statins and Musculoskeletal Conditions, Arthropathies, and Injuries
Mansi, I. A., Frei, C. R., Pugh, M. J., Makris, U. E., & Mortensen, E. M. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6184 · Cited by 131
Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry
Nanna, M. G., Navar, A. M., Zakroysky, P., Xiang, Q., Goldberg, A. C., Robinson, J., Roger, V. L., Virani, S. S., Wilson, P. W. F., Elassal, J., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1511 · Cited by 122
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Statins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
Statins and the risk of colorectal cancer: An updated systematic review and meta-analysis of 40 studies
Lytras, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1858 · Cited by 119
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin
Giugliano, R. P., KEECH, A. C., Murphy, S. A., Huber, K., Tokgozoglu, S. L., Lewis, B. S., Ferreira, J., Pineda, A. L., Somaratne, R. M., Sever, P., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.3944 · Cited by 105
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol
Schwartz, G. G., Steg, P. G., Bhatt, D. L., Bittner, V., Díaz, R., Goodman, S. G., Jukema, J. W., Kim, Y.-U., Li, Q. H., Manvelian, G. Z., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.049447 · Cited by 102
Can LDL cholesterol be too low? Possible risks of extremely low levels
OLSSON, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo-Mı́nguez, Á., Cohen, J. C., von Eckardstein, A., Farinaro, E., Müller‐Wieland, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12614 · Cited by 102
The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice
Sattar, N. A., Ginsberg, H. N., Ray, K. K., Chapman, M. J., Arca, M., Averna, M. R., Betteridge, D. J., Bhatnagar, D., Bilianou, E., Carmena, R., et al. (2014) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2014.04.001 · Cited by 99
Statins and Colorectal Cancer
Lochhead, P. J., & Chan, A. T. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.08.037 · Cited by 97
LDL Cholesterol: The Lower the Better
Martin, S. S., Blumenthal, R. S., & Miller, M. J. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.009 · Cited by 94
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
Curing atherosclerosis should be the next major cardiovascular prevention goal
Robinson, J. G., & Gidding, S. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.009 · Cited by 87
Risk identification and possible countermeasures for muscle adverse effects during statin therapy
Magni, P., Macchi, C., Morlotti, B., Sirtori, C. R., & Ruscica, M. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.01.002 · Cited by 81
Exploring association between statin use and breast cancer risk: an updated meta-analysis
Islam, M. M., Yang, H., Nguyen, P.-A., Poly, T. N., Huang, C., Kekade, S., Khalfan, A. M., Debnath, T., Li, Y., & Syed-Abdul, S. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4533-3 · Cited by 73
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
Karalis, D. G., Victor, B. M., Ahedor, L., & Liu, L. (2012) · Cholesterol · doi:10.1155/2012/861924 · Cited by 68
Value of CACS Compared With ETT and Myocardial Perfusion Imaging for Predicting Long-Term Cardiac Outcome in Asymptomatic and Symptomatic Patients at Low Risk for Coronary Disease
Chang, S. M., Nabi, F., Xu, J., Pratt, C. M., Mahmarian, A. C., Frias, M. E., & Mahmarian, J. J. (2015) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.11.008 · Cited by 67
Statin use and breast cancer survival and risk: a systematic review and meta-analysis
Wu, Q., Tu, C., Li, Y., Zhu, J., Qian, K., Li, W., & Wu, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5557 · Cited by 65
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
Ridker, P. M., Amarenco, P., Brunell, R., Glynn, R. J., Jukema, J. W., Kastelein, J. J. P., Köenig, W., Nissen, S. E., Revkin, J. H., Santos, R. D., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.05.010 · Cited by 62
Self-citation
Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries
Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 65
Statin Intolerance
Newman, C. B., & Tobert, J. A. (2015) · JAMA · doi:10.1001/jama.2015.1335 · Cited by 59
Hypercholesterolaemia – practical information for non-specialists
Soran, H., Adam, S., Mohamad, J. B., Ho, J. H., Schofield, J. D., Kwok, S., Siahmansur, T. J., Liu, Y., Syed, A. A., Dhage, S. S., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.72238 · Cited by 59
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)
Baruch, A., Mosesova, S., Davis, J. D., Budha, N. R., Vilimovskij, A., Kahn, R., Peng, K., Cowan, K. J., Harris, L. P., Gelzleichter, T. R., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.020 · Cited by 56
A common missense variant of LILRB5 is associated with statin intolerance and myalgia
Siddiqui, M. K., Maroteau, C., Veluchamy, A., Tornio, A., Tavendale, R., Carr, F., Abelega, N.-U., Carr, D. F., Bloch, K. M., Hallberg, P., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx467 · Cited by 56
Self-citation
Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials
D’Ugo, E., Libby, P., & De Caterina, R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0246 · Cited by 54
Statin-based therapy for primary and secondary prevention of ischemic stroke: A meta-analysis and critical overview
Milionis, H. J., Ntaios, G., Korompoki, E., Vemmos, K. N., & Michel, P. (2019) · International Journal of Stroke · doi:10.1177/1747493019873594 · Cited by 54
Next Steps in Primary Prevention of Coronary Heart Disease
DOMANSKI, M. J., Fuster, V., Díaz‐Mitoma, F., Grundy, S. M., Lloyd‐Jones, D. M., Mamdani, M., Roberts, R. E., Thorpe, K. E., Hall, J., Udell, J. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.857 · Cited by 50
Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management
Bandyopadhyay, D., Qureshi, A., Ghosh, S., Ashish, K., Heise, L. R., Hajra, A., & Ghosh, R. K. (2018) · Journal of Lipids · doi:10.1155/2018/8598054 · Cited by 55
Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels
Kataoka, Y., Hammadah, M., Puri, R., Duggal, B., Uno, K., Kapadia, S. R., Tuzcu, E. M., Nissen, S. E., & Nicholls, S. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.08.005 · Cited by 49
Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future
Chait, A., & Eckel, R. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3940 · Cited by 48
Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
Nishikido, T. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01752-4 · Cited by 45
Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
Kohli, P., Desai, N. R., Giugliano, R. P., Kim, J. B., Somaratne, R. M., Huang, F., Knüsel, B., McDonald, S. T., Abrahamsen, T. E., Wasserman, S. M., et al. (2012) · Clinical Cardiology · doi:10.1002/clc.22014 · Cited by 45
Inclisiran in lipid management: A Literature overview and future perspectives
Scicchitano, P., Milo, M., Mallamaci, R., Palo, M. D., Caldarola, P., Massari, F., Gabrielli, D., Colivicchi, F., & Ciccone, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112227 · Cited by 47
A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps
López-Jiménez, F. A., Simha, V., Thomas, R. J., Allison, T. G., Basu, A., Fernandes, R., Hurst, R. T., Kopecky, S. L., Kullo, I. J., Mulvagh, S. L., et al. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.06.016 · Cited by 45
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 45
Recent Clinical Studies of the Effects of Lipid-Modifying Therapies
Gotto, A. M., & Moon, J. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.003 · Cited by 44
Statins for primary prevention of venous thromboembolism
Li, L., Zhang, P., Tian, J. H., & Yang, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008203.pub3 · Cited by 42
Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events
LaRosa, J. C., Pedersen, T. R., Somaratne, R. M., & Wasserman, S. M. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.052 · Cited by 43
Can we dramatically reduce the incidence of coronary heart disease?
DOMANSKI, M. J., Lloyd‐Jones, D. M., Fuster, V., & Grundy, S. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.158 · Cited by 42
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Do, R. Q., Vogel, R. A., & Schwartz, G. G. (2013) · Current Cardiology Reports · doi:10.1007/s11886-012-0345-z · Cited by 41
Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date
McCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39
Exploring the Association between Low-Density Lipoprotein Subfractions and Major Adverse Cardiovascular Outcomes—A Comprehensive Review
Stanciulescu, L. A., Scafa‐Udriște, A., & Dorobanţu, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076669 · Cited by 45
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials.
Broncel, M., Gorzelak‐Pabiś, P., Sahebkar, A., Serejko-Banaś, K. E., Ursoniu, S., Rysz, J., Serban, M. C., Możdżan, M., & Banach, M. (2015) · PubMed Central · doi:10.5114/aoms.2015.54841 · Cited by 37
The controversy of a wider statin utilization: why?
Mansi, I. A., & Mortensen, E. M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.779667 · Cited by 37
Repurposing of Existing Statin Drugs for Treatment of Microbial Infections: How Much Promising?
Rana, R., Sharma, R., & Kumar, A. (2018) · Infectious Disorders - Drug Targets · doi:10.2174/1871526518666180806123230 · Cited by 36
Targeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 35
Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes.
Enas, E. A., Kuruvila, A. T., Khanna, P., Pitchumoni, C. S., & Mohan, V. (2013) · Europe PMC (PubMed Central) · Cited by 34
Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy
Ito, M. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r127 · Cited by 34
Cardiac Autonomic Testing and Treating Heart Disease. “A Clinical Perspective”
DePace, N. L., Mears, J. P., Yayac, M. F., & Colombo, J. (2014) · Heart International · doi:10.5301/heartint.5000216 · Cited by 31
A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs
Alla, V. M., Agrawal, V., DeNazareth, A., Mohiuddin, S., Ravilla, S., & Rendell, M. (2013) · Drugs · doi:10.1007/s40265-013-0072-9 · Cited by 33
PCSK9 Antibodies for the Treatment of Hypercholesterolemia
Gouni‐Berthold, I., & Berthold, H. K. (2014) · Nutrients · doi:10.3390/nu6125517 · Cited by 30
The Role of Aspirin, Vitamin D, Exercise, Diet, Statins, and Metformin in the Prevention and Treatment of Colorectal Cancer
Sehdev, A., & O’Neil, B. H. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0359-z · Cited by 28
Effect of statins use on risk and prognosis of breast cancer: a meta-analysis
Zhao, G., Ji, Y., Ye, Q., Ye, X., Wo, G., Chen, X., Shao, X., & Tang, J. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001151 · Cited by 28
Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis
Bekbossynova, M., Saliev, T. M., Ivanova-Razumova, T., Andossova, S., Kali, A., & Myrzakhmetova, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072352 · Cited by 27
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom, D. J., Dent, R. E., Castro, R. D. C., & Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s102564 · Cited by 27
Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines – Full report
da Silva, P. M., Duarte, J. S., HAFE, P. V., Gil, V. M., de Oliveira, J. N., & de Sousa, G. (2018) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2018.04.001 · Cited by 26
Statin-induced LDL cholesterol response and type 2 diabetes: a bidirectional two-sample Mendelian randomization study
Smit, R. A. J., Trompet, S., Leong, A., Goodarzi, M. O., Postmus, I., Warren, H. R., Theusch, E., Barnes, M. R., Arsenault, B. J., Li, X., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0125-x · Cited by 26
Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events
Sakuma, M., Iimuro, S., Shinozaki, T., Kimura, T., Nakagawa, Y., Ozaki, Y., Iwata, H., Miyauchi, K., Daida, H., Suwa, S., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02633-5 · Cited by 25
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
Colesterol LDL, cuanto más bajo mejor
Pedro‐Botet, J., & Pintó, X. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.10.003 · Cited by 23
Statin‐associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies
Shah, M., Shrestha, K., Tseng, C., Goyal, A., Liewluck, T., & Gupta, L. (2024) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.15337 · Cited by 25
Incidence of Musculoskeletal and Neoplastic Diseases in Patients on Statin Therapy: Results of a Retrospective Cohort Analysis
Mansi, I. A., Mortensen, E. M., Pugh, M. J., Wegner, M., & Frei, C. R. (2012) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31825b8edf · Cited by 22
Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies
Yang, K., Marley, A. R., Tang, H., Song, Y., Tang, J. Y., & Han, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20034 · Cited by 23
Statins, mood, sleep, and physical function: a systematic review
Swiger, K. J., Manalac, R. J., Blaha, M. J., Blumenthal, R. S., & Martin, S. S. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1758-y · Cited by 20
Fixed-dose combination of rosuvastatin and ezetimibe: treating hypercholesteremia according to cardiovascular risk
Barrios, V., & Escobar, C. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1925539 · Cited by 19
LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?
Weitgasser, R., Ratzinger, M., Hemetsberger, M., & Siostrzonek, P. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0518-2 · Cited by 19
Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1114 · Cited by 19
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1246-y · Cited by 19
Prevalence of poor lipid control in patients with premature coronary artery disease
Martínez‐Sánchez, F. D., Galarza, E. J., Posadas‐Romero, C., Medina-Urrutia Aida, X., Martínez-Alvarado, M. R., Osorio‐Alonso, H., & Juárez-Rojas, J. G. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.04.030 · Cited by 18
Advances in the treatment of dyslipidemia
Sabatine, M. S. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83gr.16001 · Cited by 17
Control lipídico en pacientes con enfermedad coronaria del Área de Salud de Cáceres (España): estudio LIPICERES
Gómez-Barrado, J. J., Ortiz, C., Gómez-Turégano, M., Gómez-Turégano, P., de Vargas, F. J. G., & Sánchez-Calderón, P. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.09.003 · Cited by 16
Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy
Sucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071882 · Cited by 21
Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective
Enas, E. A., Dharmarajan, T. S., & Varkey, B. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.03.020 · Cited by 16

Authors: Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M.
Affiliations: AstraZeneca (United States) (US)
Brigham and Women's Hospital (US)
Corresponding author: Hsia, Judith
ORCID: Hsia, Judith
Monyak, John
Ridker, Paul M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2011-04
Volume: 57
Issue: 16
Pages: 1666-1675
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2010.09.082
OpenAlex: W166112863
Cited by: 231
References: 41
Citations by year: 2026: 3 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 12 · 2021: 8 · 2020: 10 · 2019: 15 · 2018: 14 · 2017: 23 · 2016: 23 · 2015: 30 · 2014: 20 · 2013: 22 · 2012: 19
FWCI: 23.22
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 837 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca LP
AstraZeneca
Novartis
Merck
Abbott
Roche
Sanofi-Aventis
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: rosuvastatin, LDL cholesterol, cardiovascular risk reduction, high-sensitivity C-reactive protein, JUPITER trial, statin safety, all-cause mortality, major adverse cardiovascular events, myalgia, diabetes mellitus, cancer, neuropsychiatric adverse effects, hypercholesterolemia, inflammation, cardiovascular disease prevention
MeSH terms: Rosuvastatin Calcium, Aged, Cardiovascular Diseases, Female, Fluorobenzenes, Follow-Up Studies, Humans, Cholesterol, LDL, Male, Middle Aged, Pyrimidines, Sulfonamides, Cohort Studies, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks